Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veritas In Silico's revenue for the
three
months ended in Jun. 2026 was 円0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was 円84.82 Mil.
Veritas In Silico's Revenue per Share for the
three
months ended in Jun. 2026 was 円0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was 円13.08.
Warning Sign:
Veritas In Silico Inc revenue per share has been in decline over the past 3 years.
During the past 5 years, Veritas In Silico's highest 3-Year average Revenue per Share Growth Rate was 48.00% per year. The lowest was -24.40% per year. And the median was 11.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Veritas In Silico Revenue Related Terms
Veritas In Silico Revenue Historical Data
* Premium members only.
The historical data trend for Veritas In Silico's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Veritas In Silico's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veritas In Silico Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veritas In Silico's Revenue distribution charts can be found below:
* The bar in red indicates where Veritas In Silico's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円84.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veritas In Silico (TSE:130A) has a Revenue of 円84.82 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Veritas In Silico and its competitors.
Is Veritas In Silico's Revenue too high?
Veritas In Silico's current Revenue is 円84.82 Mil. Overall, Veritas In Silico has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's Revenue compare to VRTX and REGN?
Veritas In Silico's Revenue of 円84.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Veritas In Silico and its competitors. Veritas In Silico's current Revenue is 円84.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Based on GuruFocus' analysis, Veritas In Silico (TSE:130A) is currently considered Significantly Overvalued. The stock's GF Value™ is 円267.11, compared to a current price of 円446.00 — trading 67% above its estimated fair value. The current Revenue is 円84.82 Mil. Veritas In Silico's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current Revenue is 円84.82 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veritas In Silico (TSE:130A) Overvalued in 2026?
Based on GuruFocus' analysis, Veritas In Silico stock appears to be overvalued.
The current stock price of 円446.00 is trading 67% above its estimated GF Value™ of 円267.11.
GuruFocus considers Veritas In Silico to be Significantly Overvalued.
Key valuation signals for TSE:130A:
Revenue: 円84.82 Mil
GF Value™: 円267.11 vs. price of 円446.00 (67% above fair value)
No single metric tells the full story. See the TSE:130A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
28GF Score
Get the complete analysis for TSE:130A
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:130A has been successfully added to your 
